Citigroup Lowers Health Catalyst (NASDAQ:HCAT) Price Target to $10.00

Health Catalyst (NASDAQ:HCAT) had its price objective reduced by equities researchers at Citigroup from $10.50 to $10.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price objective would indicate a potential upside of 44.09% from the stock’s current price.

Other research analysts have also issued reports about the company. Evercore ISI lifted their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a report on Wednesday. Royal Bank of Canada lifted their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research note on Friday, October 4th. Finally, Piper Sandler reiterated an “overweight” rating and set a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.45.

Health Catalyst Price Performance

NASDAQ:HCAT traded down $0.42 during mid-day trading on Friday, reaching $6.94. The stock had a trading volume of 236,109 shares, compared to its average volume of 505,904. The stock has a 50-day simple moving average of $7.81 and a two-hundred day simple moving average of $7.52. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst has a 12 month low of $5.42 and a 12 month high of $11.41. The stock has a market capitalization of $422.29 million, a PE ratio of -5.14 and a beta of 1.36.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. During the same quarter last year, the company posted ($0.22) earnings per share. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. On average, equities analysts anticipate that Health Catalyst will post -0.33 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $8.94, for a total transaction of $67,050.00. Following the transaction, the insider now directly owns 236,950 shares in the company, valued at approximately $2,118,333. This represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Duncan Gallagher sold 4,500 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $6.93, for a total value of $31,185.00. Following the completion of the sale, the director now owns 69,938 shares of the company’s stock, valued at $484,670.34. The trade was a 6.05 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 68,342 shares of company stock valued at $554,695. Company insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Principal Financial Group Inc. increased its stake in shares of Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after buying an additional 1,907 shares during the period. Rhumbline Advisers increased its position in Health Catalyst by 9.1% during the 2nd quarter. Rhumbline Advisers now owns 91,111 shares of the company’s stock valued at $582,000 after purchasing an additional 7,589 shares during the period. American Century Companies Inc. raised its holdings in Health Catalyst by 1.4% in the 2nd quarter. American Century Companies Inc. now owns 683,464 shares of the company’s stock worth $4,367,000 after purchasing an additional 9,466 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Health Catalyst by 17.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 331,847 shares of the company’s stock worth $2,121,000 after purchasing an additional 50,297 shares during the period. Finally, Primecap Management Co. CA boosted its stake in shares of Health Catalyst by 14.7% during the 2nd quarter. Primecap Management Co. CA now owns 2,379,462 shares of the company’s stock valued at $15,205,000 after purchasing an additional 305,079 shares in the last quarter. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.